This regulatory greenlight de-risks the early development path for SIL204. Traders should monitor upcoming trial initiation in Q2 2026 and future data readouts. Given the high unmet need in KRAS-driven cancers, successful clinical results could lead to significant upside, though current market cap reflects high risk.
Price Chart
Executive Summary
Silexion Therapeutics has received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for its RNAi therapy SIL204 in locally advanced pancreatic cancer, marking its transition to a clinical-stage company. The trial is expected to begin in Q2 2026, following positive preclinical results and completed toxicology studies, with plans for additional regulatory filings in Europe.
Key Facts
- Received formal approval from Israeli Ministry of Health to initiate Phase 2/3 trial for SIL204 in pancreatic cancer
- Positive preclinical results showing significant anti-tumor activity in multiple models
- Toxicology studies successfully completed
- Trial expected to start in Q2 2026, pending site activation
- Plans to file for Phase 2/3 trial in Germany by end of Q1 2026, EU-wide filings in early 2027
- SIL204 targets broad range of KRAS mutations, present in >90% of pancreatic cancers
Financial Impact
Potential long-term value creation if clinical trials succeed; no immediate revenue impact
Risk Factors
- Clinical trial may face delays in site activation or enrollment
- Preclinical success may not translate to human efficacy
- Company may need to raise additional capital, leading to dilution
- Regulatory hurdles in other jurisdictions (Germany, EU) may arise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1890 (−22.89%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1890 (+28.08%) |
Sep 30, 2026 26d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1890 (−31.77%) |
Sep 30, 2026 26d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1890 (+31.84%) |
Sep 29, 2026 27d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1890 (+40.57%) |
Sep 29, 2026 27d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1890 (+40.64%) |
Sep 28, 2026 28d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1890 (−23.91%) |
Sep 28, 2026 28d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1890 (−23.91%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1890 (+23.91%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1890 (+55.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers